APA

Kereiakes D. J., Broderick T. M., Roth E. M., Whang D., Mueller M., Lacock P., Anderson L. C., Howard W., Blanck C., Schneider J. & Abbottsmith C. A. (20000310). High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. : Journal of thrombosis and thrombolysis.

Chicago

Kereiakes D J, Broderick T M, Roth E M, Whang D, Mueller M, Lacock P, Anderson L C, Howard W, Blanck C, Schneider J and Abbottsmith C A. 20000310. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. : Journal of thrombosis and thrombolysis.

Harvard

Kereiakes D. J., Broderick T. M., Roth E. M., Whang D., Mueller M., Lacock P., Anderson L. C., Howard W., Blanck C., Schneider J. and Abbottsmith C. A. (20000310). High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. : Journal of thrombosis and thrombolysis.

MLA

Kereiakes D J, Broderick T M, Roth E M, Whang D, Mueller M, Lacock P, Anderson L C, Howard W, Blanck C, Schneider J and Abbottsmith C A. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists. : Journal of thrombosis and thrombolysis. 20000310.